Publications

  1. Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, Ahlskog JE, Caselli RJ, Jacobson S, Sabbagh M, Adler C, Woodruff B, Beach TG, Iranzo A, Gelpi E, Santamaria J, Tolosa E, Singer C, Mash DC, Luca C, Arnulf I, Duyckaerts C, Schenck CH, Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013 Mar 06. [Epub ahead of print] 2309463
    View PubMed
  2. Beach TG, Adler CH, Dugger BN, Serrano G, Hidalgo J, Henry-Watson J, Shill HA, Sue LI, Sabbagh MN, Akiyama H, Arizona Parkinson's Disease Consortium. Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol. 2013 Feb; 72(2):130-6. 2307589
    View PubMed
  3. Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG, Arizona Parkinson's Disease Consortium. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol. 2013 Feb; 72(2):119-29. 2297881
    View PubMed
  4. Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, Akiyama H, Serrano GE, Sue LI, Beach TG. Changes in properties of serine 129 phosphorylated -synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol. 2013; 240(1):190-204. 2293526
  5. Maarouf CL, Beach TG, Adler CH, Malek-Ahmadi M, Kokjohn TA, Dugger BN, Walker DG, Shill HA, Jacobson SA, Sabbagh MN, Roher AE. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. Biomarker Insights. 2013; 8:19-28. 2316224
  6. Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, Greene JG. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 2012 Nov; 124(5):665-80. Epub 2012 Sep 02. 2286753
    View PubMed
  7. Driver-Dunckley ED, Adler CH. Movement disorders and sleep. Neurol Clin. 2012 Nov; 30(4):1345-58. 2279659
    View PubMed
  8. Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 2012 Nov; 22(6):745-56. Epub 2012 Apr 12. 2227604
    View PubMed
  9. Jiang H, He P, Adler CH, Shill H, Beach TG, Li R, Shen Y. Bid signal pathway components are identified in the temporal cortex with Parkinson disease. Neurology. 2012 Oct 23; 79(17):1767-73. Epub 2012 Sep 26. 2273185
    View PubMed
  10. Maarouf CL, Beach TG, Adler CH, Shill HA, Sabbagh MN, Wu T, Walker DG, Kokjohn TA, Roher AE, Arizona PD Consortium. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol Res. 2012 Sep; 34(7):669-76. 2275166
    View PubMed
  11. Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG, Arizona Parkinson's Disease Consortium. Altered pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol. 2012 Jun; 71(6):520-30. 2246723
    View PubMed
  12. Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K, PARS Investigators. Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord. 2012 Mar; 27(3):406-12. Epub 2012 Jan 11. 2275132
    View PubMed
  13. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012 Mar; 27(3):349-56. Epub 2012 Jan 24. 2235887
    View PubMed
  14. Dugger BN, Serrano GE, Sue LI, Walker DG, Adler CH, Shill HA, Sabbagh MN, Caviness JN, Hidalgo J, Saxon-Labelle M, Chiarolanza G, Mariner M, Henry-Watson J, Beach TG, the Arizona Parkinson's Disease Consortium. Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. J Parkinsons Dis. 2012 Jan 1; 2(1):57-65. 2275075
    View PubMed
  15. Shill HA, Adler CH, Beach TG. Pathology in essential tremor. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1:S135-7. 2221570
    View PubMed
  16. Shill HA, Adler CH, Beach TG, Lue LF, Caviness JN, Sabbagh MN, Sue LI, Walker DG. Brain biochemistry in autopsied patients with essential tremor. Mov Disord. 2012 Jan; 27(1):113-7. Epub 2011 Oct 28. 2225299
    View PubMed
  17. *Damian A, Adler CH, Hentz JG, Shill HA, Caviness JN, Sabbagh MN, Evidente VGH, Beach TG, Driver-Dunckley E. Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. Parkinsonism Relat Disord. 2012; 18(10):1089-93. 2293282
  18. Caviness JN, Adler CH, Hentz JG, Shill HA, Evidente VG, Driver-Dunckley ED, Sabbagh MN, Sue L, Beach TG. Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol. 2011 Dec; 122(12):2426-32. Epub 2011 May 26. 2166908
    View PubMed
  19. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011 Oct; 12(9):906-13. Epub 2011 Oct 05. 2208877
    View PubMed
  20. Evidente VG, Premkumar AP, Adler CH, Caviness JN, Driver-Dunckley E, Lyons MK. Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson's disease. Acta Neurol Scand. 2011 Sep; 124(3):211-4. Epub 2010 Oct 25. 2121263
    View PubMed
  21. Adler CH, Crews D, Kahol K, Santello M, Noble B, Hentz JG, Caviness JN. Are the yips a task-specific dystonia or "golfer's cramp"? Mov Disord. 2011 Sep; 26(11):1993-6. Epub 2011 Jun 14. 2169955
    View PubMed
  22. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Troster AI, Weintraub D. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011 Aug 15; 26(10):1814-24. Epub 2011 Jun 09. 2195313
    View PubMed
  23. Klassen BT, Hentz JG, Shill HA, Driver-Dunckley E, Evidente VG, Sabbagh MN, Adler CH, Caviness JN. Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology. 2011 Jul 12; 77(2):118-24. Epub 2011 Jun 01. 2167787
    View PubMed
  24. Adler CH, Hentz JG, Shill HA, Sabbagh MN, Driver-Dunckley E, Evidente VG, Jacobson SA, Beach TG, Boeve B, Caviness JN. Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Parkinsonism Relat Disord. 2011 Jul; 17(6):456-8. Epub 2011 Apr 08. 2157508
    View PubMed
  25. Caviness JN, Lue LF, Beach TG, Hentz JG, Adler CH, Sue L, Sadeghi R, Driver-Dunckley E, Evidente VG, Sabbagh MN, Shill HA, Walker DG. Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord. 2011 Jul; 26(8):1436-42. Epub 2011 May 03. 2163842
    View PubMed
  26. Evidente VG, Adler CH, Sabbagh MN, Connor DJ, Hentz JG, Caviness JN, Sue LI, Beach TG. Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP? Parkinsonism Relat Disord. 2011 Jun; 17(5):365-71. Epub 2011 Mar 21. 2155488
    View PubMed
  27. Papay K, Mamikonyan E, Siderowf AD, Duda JE, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Weintraub D. Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. Parkinsonism Relat Disord. 2011 Mar; 17(3):153-5. Epub 2010 Dec 24. 2151439
    View PubMed
  28. Adler CH, Shill HA, Beach TG. Essential tremor and Parkinson's disease: lack of a link. Mov Disord. 2011 Feb 15; 26(3):372-7. Epub 2011 Jan 31. 2147416
    View PubMed
  29. Caviness JN, Lue L, Adler CH, Walker DG. Parkinson's disease dementia and potential therapeutic strategies. CNS Neurosci Ther. 2011 Feb; 17(1):32-44. Epub 2010 Dec 28. 2141669
    View PubMed
  30. Damian AM, Jacobson SA, Hentz JG, Belden CM, Shill HA, Sabbagh MN, Caviness JN, Adler CH. The Montreal Cognitive Assessment and the mini-mental state examination as screening instruments for cognitive impairment: item analyses and threshold scores. Dement Geriatr Cogn Disord. 2011; 31(2):126-31. Epub 2011 Jan 29. 2167017
    View PubMed
  31. Adler CH. Premotor symptoms and early diagnosis of Parkinson's disease. Int J Neurosci. 2011; 121 Suppl 2:3-8. 2204848
    View PubMed
  32. Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, Sutch SM, Brin MF, Papapetropoulos S. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011; 11:140. Epub 2011 Nov 04. 2211504
    View PubMed
  33. Adler CH, Beach TG. Variability of diffuse plaques and amyloid angiopathy in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 2010 Dec; 120(6):831. Epub 2010 Oct 13. 2118548
    View PubMed
  34. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med. 2010 Oct 6; 2(52):52ra73. 2143881
    View PubMed
  35. Evidente VG, Adler CH. An update on the neurologic applications of botulinum toxins. Curr Neurol Neurosci Rep. 2010 Sep; 10(5):338-44. 2103449
    View PubMed
  36. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG, Arizona Parkinson's Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010 Jun; 119(6):689-702. Epub 2010 Mar 21. 2143927
    View PubMed
  37. Adler CH, Connor DJ, Hentz JG, Sabbagh MN, Caviness JN, Shill HA, Noble B, Beach TG. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord. 2010 Apr 15; 25(5):642-6. 1987764
    View PubMed
  38. McKinnon J, Evidente V, Driver-Dunckley E, Premkumar A, Hentz J, Shill H, Sabbagh M, Caviness J, Connor D, Adler C. Olfaction in the elderly: a cross-sectional analysis comparing Parkinson's disease with controls and other disorders. Int J Neurosci. 2010 Jan; 120(1):36-9. 1985092
    View PubMed
  39. Adler CH. Mild cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S81-2. 1983146
    View PubMed
  40. Cobb SA, Wider C, Ross OA, Mata IF, Adler CH, Rajput A, Rajput AH, Wu RM, Hauser R, Josephs KA, Carr J, Gwinn K, Heckman MG, Aasly JO, Lynch T, Uitti RJ, Wszolek ZK, Kapatos G, Farrer MJ. GCH1 in darly-onset Parkinson's disease. Mov Disord. 2009 Oct 30; 24(14):2070-5. 1975937
    View PubMed
  41. Cobb SA, Wider C, Ross OA, Mata IF, Adler CH, Rajput A, Rajput AH, Wu RM, Hauser R, Josephs KA, Carr J, Gwinn K, Heckman MG, Aasly JO, Lynch T, Uitti RJ, Wszolek ZK, Kapatos G, Farrer MJ. GCH1 in early-onset Parkinson's disease. Mov Disord. 2009 Oct 30; 24(14):2070-5. 1960621
    View PubMed
  42. Adler CH. Perioperative use of botulinum toxins. Toxicon. 2009 Oct; 54(5):654-7. Epub 2008 Dec 03. 1915103
    View PubMed
  43. Driver-Dunckley E, Connor D, Hentz J, Sabbagh M, Silverberg N, Hernandez J, Vedders L, Evidente VG, Shill H, Caviness J, Adler C. No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome. Mov Disord. 2009 Sep 15; 24(12):1840-2. 1953788
    View PubMed
  44. Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord. 2009 Jul 30; 24(10):1461-7. 1981949
    View PubMed
  45. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Walker DG, Beach TG. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):295-7. 1966675
    View PubMed
  46. Sabbagh MN, Sandhu SS, Farlow MR, Vedders L, Shill HA, Caviness JN, Connor DJ, Sue L, Adler CH, Beach TG. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):229-33. 1966677
    View PubMed
  47. Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, Adler CH, Caviness JN, Wingerchuk DM. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist. 2009 Jul; 15(4):234-7. 1952577
    View PubMed
  48. Vilarino-Guell C, Wider C, Soto-Ortolaza AI, Cobb SA, Kachergus JM, Keeling BH, Dachsel JC, Hulihan MM, Dickson DW, Wszolek ZK, Uitti RJ, Graff-Radford NR, Boeve BF, Josephs KA, Miller B, Boylan KB, Gwinn K, Adler CH, Aasly JO, Hentati F, Destee A, Characterization of DCTN1 genetic variability in neurodegeneration. Neurology. 2009 Jun 9; 72(23):2024-8. 1946894
    View PubMed
  49. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL III, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG. Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (Berl). 2009 Jun; 117(6):613-34. 1982679
    View PubMed
  50. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ, TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 Mar 15; 24(4):564-73. 1981894
    View PubMed
  51. Beach TG, White CL III, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, Akiyama H, Adler CH. Olfactory bulb alpha -synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol (Berl) 2009 Feb; 117(2):169-74. 1947856
    View PubMed
  52. Lyons MK, Adler CH, Bansberg SF, Evidente VGH. Spasmodic dysphonia may respond to bilateral thalamic deep brain stimulation. Afr J of Neurol Sci. 2009; 28(1):10-811. 1995261
  53. Alvarez MV, Driver-Dunckley EE, Caviness JN, Adler CH, Evidente VG. Case series of painful legs and moving toes: clinical and electrophysiologic observations. Mov Disord. 2008 Oct 30; 23(14):2062-6. 1915711
    View PubMed
  54. Ludlow CL, Adler CH, Berke GS, Bielamowicz SA, Blitzer A, Bressman SB, Hallett M, Jinnah HA, Juergens U, Martin SB, Perlmutter JS, Sapienza C, Singleton A, Tanner CM, Woodson GE. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008 Oct; 139(4):495-505. 1955109
    View PubMed
  55. Sparks DL, Ziolkowski C, Connor D, Beach T, Adler C, Sabbagh M. Copper and cognition in Alzheimer's disease and Parkinson's disease. Cell Biology & Toxicology. 2008 Oct; 24(5):426-30. 1954970
    View PubMed
  56. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, Leverenz JB, Roncaroli F, Buttini M, Hladik CL, Sue LI, Noorigian JV, Adler CH. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 2008 Sep; 116(3):277-88. Epub 2008 Jul 15. 1949970
    View PubMed
  57. Stamper C, Siegel A, Liang WS, Pearson JV, Stephan DA, Shill H, Connor D, Caviness JN, Sabbagh M, Beach TG, Adler CH, Dunckley T. Neuronal gene expression correlates of Parkinson's disease with dementia. Mov Disord. 2008 Aug 15; 23(11):1588-95. 1955131
    View PubMed
  58. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008 Jun; 63(6):743-50. 1891610
    View PubMed
  59. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, Parkinson Study Group, Leurgans S. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9. 1905024
    View PubMed
  60. Shill HA, Adler CH, Sabbagh MN, Connor DJ, Caviness JN, Hentz JG, Beach TG. Pathologic findings in prospectively ascertained essential tremor subjects. Neurology. 2008 Apr 15; 70(16 Pt 2):1452-5. 1909303
    View PubMed
  61. Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 2008 Apr; 115(4):445-51. Epub 2007 Nov 06. 1902589
    View PubMed
  62. McKinnon JH, Demaerschalk BM, Caviness JN, Wellik KE, Adler CH, Wingerchuk DM. Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders? Neurologist. 2007 Nov; 13(6):382-5. 1867416
    View PubMed
  63. Beach TG, Sue LI, Walker DG, Lue LF, Connor DJ, Caviness JN, Sabbagh MN, Adler CH. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol (Berl) 2007 Oct; 114(4):419-24. Epub 2007 Jul 17. 1844542
    View PubMed
  64. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):249-55. 1844480
    View PubMed
  65. Caviness JN, Hentz JG, Evidente VG, Driver-Dunckley E, Samanta J, Mahant P, Connor DJ, Sabbagh MN, Shill HA, Adler CH. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism Relat Disord. 2007 Aug; 13(6):348-54. Epub 2007 Mar 08. 1834797
    View PubMed
  66. Trosch RM, Adler CH, Pappert EJ. Botulinum toxin type B (Myobloc(R)) in subjects with hemifacial spasm: Results from an open-label, dose-escalation safety study. Mov Disord. 2007 Jul 15; 22(9):1258-64. 1837035
    View PubMed
  67. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 2007 Jul 15; 22(9):1272-7. 1837036
    View PubMed
  68. Snyder CH, Adler CH. The patient with Parkinson's disease: part I-treating the motor symptoms; part II-treating the nonmotor symptoms. J Am Acad Nurse Pract. 2007 Apr; 19(4):179-97. 1817556
    View PubMed
  69. Melquist S, Craig DW, Huentelman MJ, Crook R, Pearson JV, Baker M, Zismann VL, Gass J, Adamson J, Szelinger S, Corneveaux J, Cannon A, Coon KD, Lincoln S, Adler C, Tuite P, Calne DB, Bigio EH, Uitti RJ, Wszolek ZK, Golbe LI, Caselli RJ, Graff-Radford N, Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet. 2007 Apr; 80(4):769-78. Epub 2007 Mar 08. 1818678
    View PubMed
  70. Toft M, Mata IF, Ross OA, Kachergus J, Hulihan MM, Haugarvoll K, Stone JT, Blazquez M, Gibson JM, Aasly JO, White LR, Lynch T, Adler CH, Gwinn-Hardy K, Farrer MJ. Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. Mov Disord. 2007 Feb 15; 22(3):389-92. 1812271
    View PubMed
  71. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007 Jan 2; 68(1):20-8. 2264424
    View PubMed
  72. Sabbagh MN, Lahti T, Connor DJ, Caviness JN, Shill H, Vedders L, Mahant P, Samanta J, Burns RS, Evidente VG, Driver-Dunckley E, Reisberg B, Bircea S, Adler CH. Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease. Dement Geriatr Cogn Disord. 2007; 24(5):327-34. Epub 2007 Sep 13. 1848862
    View PubMed
  73. Langbehn DR, Paulsen JS, Hedges P, McCusker E, Pearce S, Trent R, Abwender D, Como P, Gardiner I, Hickey C, Kayson E, Kieburtz K, Marshall F, Pearson N, Shoulson I, Zimmerman C, Louis E, Marder K, Moskowitz C, Polanco C, Taylor S, Zubin N, Brown C, Predictors of diagnosis in Huntington disease. Neurology. 2007; 68(20):1710-7. 1975881
    View PubMed
  74. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5. 1799729
    View PubMed
  75. Driver-Dunckley E, Evidente VG, Adler CH, Hillman R, Hernandez J, Fletcher G, Lyons MK. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord. 2006 Aug; 21(8):1287-9. 1779547
    View PubMed
  76. Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I, Parkinson Study Group. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord. 2006 May; 21(5):616-23. 1997914
    View PubMed
  77. Caviness JN, Liss JM, Adler C, Evidente V. Analysis of high-frequency electroencephalographic-electromyographic coherence elicited by speech and oral nonspeech tasks in Parkinson's disease. J Speech Lang Hear Res. 2006 Apr; 49(2):424-38. 1775640
    View PubMed
  78. Caviness JN, Shill HA, Sabbagh MN, Evidente VG, Hernandez JL, Adler CH. Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease. Mov Disord. 2006 Apr; 21(4):492-9. 1760748
    View PubMed
  79. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006 Mar 14; 66(5):664-71. Epub 2006 Feb 15. 2264427
    View PubMed
  80. Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, Stern M, Goetz C, Nutt J, Goren S, Sayag N, Scolnik M, Levy R, Eyal E, Salzman P, Pagano M, Parkinson Study Group. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb; 63(2):210-6. 1968885
    View PubMed
  81. Mata IF, Bodkin CL, Adler CH, Lin SC, Uitti RJ, Farrer MJ, Wszolek ZK. Genetics of restless legs syndrome. Parkinsonism Relat Disord. 2006 Jan; 12(1):1-7. 1747075
    View PubMed
  82. Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, Lopez J, Ziolkowski C, Lochhead J, Browne P. Cholesterol, copper and A beta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Current Alzheimer Research. 2005 Dec; 2(5):527-39. 1749913
    View PubMed
  83. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W, Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005 Nov 8; 65(9):1423-9. 1809797
    View PubMed
  84. Thorpy MJ, Adler CH. Parkinson's disease and sleep. Neurol Clin. 2005 Nov; 23(4):1187-208. 1736434
    View PubMed
  85. Sabbagh MN, Silverberg N, Bircea S, Majeed B, Samant S, Caviness JN, Reisberg B, Adler CH. Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? Parkinsonism Relat Disord. 2005 Aug; 11(5):311-5. 1729897
    View PubMed
  86. Adler CH, Thorpy MJ. Sleep issues in Parkinson's disease. Neurology. 2005 Jun 28; 64(12 Suppl 3):S12-S20. 1721422
    View PubMed
  87. Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord. 2005 Apr; 20(Suppl 11):S23-9. 1720321
    View PubMed
  88. Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H, The United States-Venezuela Huntington's Disease Collaborative Research Group, The Huntington Study Group. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord. 2005 Mar; 20(3):293-7. 1809794
    View PubMed
  89. Wunderlich GR, Evans KR, Sills T, Pollentier S, Reess J, Allen RP, Hening W, Walter AS, The International Restless Legs Syndrome Study Group. An item response analysis of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep med. 2005 Mar; 6(2):131-9. 1809795
  90. Toft M, Aasly J, Bisceglio G, Adler CH, Uitti RJ, Krygowska-Wajs A, Lynch T, Wszolek ZK, Farrer MJ. Parkinsonism, FXTAS, and FMR1 premutations. Mov Disord. 2005 Feb; 20(2):230-3. 1694418
    View PubMed
  91. Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, Edwards BW, Krein-Jones K, Caviness JN. Botulinum toxin type A for treating voice tremor. Arch Neurol. 2004 Sep; 61(9):1416-20. 1663737
    View PubMed
  92. Adler CH, Bansberg SF, Krein-Jones K, Hentz JG. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord. 2004 Sep; 19(9):1075-9. 1665809
    View PubMed
  93. Pittock SJ, Parrett T, Adler CH, Parisi JE, Dickson DW, Ahlskog JE. Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology. Mov Disord. 2004 Jun; 19(6):695-9. 1652842
    View PubMed
  94. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson WM, Hentz JG. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology. 2004 Apr 27; 62(8):1405-7. 1644246
    View PubMed
  95. Beach TG, Walker DG, Sue LI, Newell A, Adler CC, Joyce JN. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. J Neuropathol Exp Neurology. 2004 Apr; 63(4):329-37. 1642956
    View PubMed
  96. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004; 351:2498-2508. 1809963
    View PubMed
  97. Van Gemmert AWA, Adler CH, Stelmach GE. Parkinson's disease patients undershoot target size in handwriting and similar tasks. Journal of Neurology, Neurosurgery & Psychiatry. 2003 Nov; 74(11):1502-8. 1429016
    View PubMed
  98. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. alpha-synuclein locus triplication causes Parkinson's disease. Science. 2003 Oct 31; 302(5646):841. 1422288
    View PubMed
  99. Caviness JN, Adler CH, Sabbagh MN, Connor DJ, Hernandez JL, Lagerlund TD. Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1157-62. 1419999
    View PubMed
  100. Evidente VG, Caviness JN, Adler CH. Case studies in movement disorders. Semin Neurol. 2003 Sep; 23(3):277-84. 1431525
    View PubMed
  101. Romero DH, Van Gemmert AWA, Adler CH, Bekkering H, Stelmach GE. Altered aiming movements in Parkinson's disease patients and elderly adults as a function of delays in movement onset. Exp Brain Res. 2003 Jul; 151(2):249-61. 1407465
    View PubMed
  102. Beach TG, Sue L, Scott S, Layne K, Newell A, Walker D, Baker M, Sahara N, Yen SH, Hutton M, Caselli R, Adler C, Connor D, Sabbagh M. Hippocampal sclerosis dementia with tauopathy. Brain Pathol. 2003 Jul; 13(3):263-78. 1425169
    View PubMed
  103. Romero DH, Van Gemmert AWA, Adler CH, Bekkering H, Stelmach GE. Time delays prior to movement alter the drawing kinematics of elderly adults. Human Movement Science. 2003 Apr; 22(2):207-20. 1431642
    View PubMed
  104. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord. 2003 Mar; 18(3):287-93. 1325090
    View PubMed
  105. Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, The Dystonia Study Group. Rating scales for dystonia: A multicenter assessment. Mov Disorders. 2003; 18:303-12. 1696405
  106. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montlaisir J, the participants in the RLS Diagnosis Epidemiology workshop at the NIH, in collaboration with members of the International RLS Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health Sleep Medicine. 2003; 4:101-19. 1696410
  107. Adler CH, Thorpy MJ. Awake and Involved: Addressing excessive daytime sleepiness in patients with Parkinson’s disease, Overview of Parkinson’s disease (Review Article). The Treatment Reporter Neurology. 2003(Part 1). 1696601
  108. Thorpy MJ, Adler CH. Awake and Involved: Addressing excessive daytime sleepiness in patients with Parkinson’s disease, Sleep issues in Parkinson’s disease (Review Article). The Treatment Reporter Neurology. 2003; Part 2. 1696603
  109. The International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group Rating Scale for Restless Legs Syndrome. Sleep Medicine. 2003;4:121-32. 1328610
    View PubMed
  110. Smith AM, Adler CH, Crews D, Wharen RE, Laskowski ER, Barnes K, Bell CV, Pelz D, Brennan RD, Smith J, Sorenson MC, Kaufman KR. The 'Yips' in golf - A continuum between a focal dystonia and choking. Sports Med. 2003; 33(1):13-31. 1317927
    View PubMed
  111. Contreras-Vidal JL, Teulings HL, Stelmach GE, Adler CH. Adaptation to changes in vertical display gain during handwriting in Parkinson's disease patients, elderly and young controls. Parkinsonism & Related Disorders. 2002 Dec; 9(2):77-84. 1317328
    View PubMed
  112. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism & Related Disorders. 2002 Dec; 9(2):103-10. 1317329
    View PubMed
  113. Liss JM, Spitzer SM, Caviness JN, Adler C. The effects of familiarization on intelligibility and lexical segmentation in hypokinetic and ataxic dysarthria. J Acoust Soc Am. 2002 Dec; 112(6):3022-30. 1317751
    View PubMed
  114. Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, Adler CH. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D-3 and not D-2 receptors. Brain Res. 2002 Nov 15; 955(1-2):138-52. 1317379
    View PubMed
  115. Korczyn AD, Thalamas C, Adler CH. Dosing with ropinirole in a clinical setting. Acta Neurol Scand. 2002 Oct; 106(4):200-4. 1316165
    View PubMed
  116. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Small-amplitude cortical myoclonus in Parkinson's disease: Physiology and clinical observations. Mov Disord. 2002 Jul; 17(4):657-62. 1315076
    View PubMed
  117. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22. 1315677
    View PubMed
  118. Vernino S, Tuite P, Adler CH, Meschia JF, Boeve BF, Boasberg P, Parisi JE, Lennon VA. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol. 2002 May; 51(5):625-30. 1315583
    View PubMed
  119. Teulings HL, Contreras-Vidal JL, Stelmach GE, Adler CH. Adaptation of handwriting size under distorted visual feedback in patients with Parkinson's disease and elderly and young controls. Journal of Neurology, Neurosurgery & Psychiatry. 2002 Mar; 72(3):315-24. 1008346
    View PubMed
  120. Adler CH. Relevance of motor complications in Parkinson's disease. Neurology. 2002 Feb 26; 58(4 Suppl 1):S51-6. 1008382
    View PubMed
  121. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Hentz JG, Manfred MS, Muenter D. Motor unit number estimates in idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2002 Jan; 8(3):161-4. 1008085
    View PubMed
  122. Adler CH, Factor SA, Brin M, Sethi KD. Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia. Mov Disord. 2002 Jan; 17(1):158-61. 1007619
    View PubMed
  123. Adler CH. Diagnosing and treating restless legs syndrome. Women's Health Orthopedic Edition. 2002; 5:54-8. 1638867
    View PubMed
  124. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Myoclonus in Lewy body disorders. Adv Neurol. 2002; 89:23-30. 1639541
    View PubMed
  125. Adler CH. Managing movement disorders with botulinum toxins: An effective approach for dystonia, tics, tremor, and hemifacial spasm (Review Article). Women’s Health in Primary Care. 2002; 5:707-19. 1696606
  126. Adler CH, Joyce JN. Collaboration Amongst Arizona Parkinson’s Disease Research Centers-Parkinson’s Disease Center Without Walls (Review Article). AZ Parkinson’s Disease Report. 2002. 1696599
  127. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson’s disease: The TEMPO study. Arch Neurol. 2002; 59:1937-43. 1696402
    View PubMed
  128. Evidente VG, Caviness JN, Adler CH, Gwinn-Hardy KA, Pratley RE. Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. Mov Disord. 2001 Sep; 16(5):924-7. 1006384
    View PubMed
  129. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I, Huntington Study Group. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 2001 Aug 28; 57(4):658-62. 1979783
    View PubMed
  130. Joyce JN, Ryoo H, Gurevich EV, Adler C, Beach T. Ventral striatal D(3) receptors and Parkinson's Disease. Parkinsonism Relat Disord. 2001 Jul; 7(3):225-230. 1005571
    View PubMed
  131. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12; 56(11):1523-8. 1005198
    View PubMed
  132. Alberts JL, Adler CH, Saling M, Stelmach GE. Prehension patterns in restless legs syndrome patients. Parkinsonism & Related Disorders. 2001 Apr; 7(2):143-148. 1005051
    View PubMed
  133. Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology. 2001 Feb 27; 56(4):455-62. 1979767
    View PubMed
  134. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Hentz JG, Muenter MD. Motor Unit Number Estimates in Idiopathic Parkinson’s Disease. Parkinsonism and Related Disorders. 2001; 8:161-4. 1696397
  135. Adler CH. Ten commonly asked questions about initiating treatment for Parkinson’s disease (Review Article). The Neurologist. 2001; 7(3):188-92. 1696593
  136. Adler CH. Diagnosing and treating restless legs syndrome (Review Article). Women’s Health In Primary Care. 2001; 4:224-8. 1696594
  137. Adler CH. Diagnosing and treating restless legs syndrome (Review Article). Women’s Health Gynecology Edition. 2001; 1:371-8. 1696598
  138. Pennachio DL, Consultants. Parkinson’s disease: Progress along the continuum of care (Review Article). Patient Care. 2000 Dec. 1696586
  139. Adler CH. Questions and answers about clinical trials (Review Article). Nightwalkers: Restless Legs Syndrome Newsletter. 2000 Nov. 1696592
  140. Alberts JL, Saling M, Adler CH, Stelmach GE. Disruptions in the reach-to-grasp actions of Parkinson's patients. Exp Brain Res. 2000 Oct; 134(3):353-62. 1012648
    View PubMed
  141. Adler CH. Strategies for controlling dystonia. Overview of therapies that may alleviate symptoms. Postgrad Med. 2000 Oct; 108(5):151-2, 155-6, 159-60. 1012661
    View PubMed
  142. Cooper C, Evidente VG, Hentz JG, Adler CH, Caviness JN, Gwinn-Hardy K. The effect of temperature on hand function in patients with tremor. J Hand Ther. 2000 Oct-Dec; 13(4):276-88. 1013559
    View PubMed
  143. Liss JM, Spitzer SM, Caviness JN, Adler C, Edwards BW. Lexical boundary error analysis in hypokinetic and ataxic dysarthria. J Acoust Soc Am. 2000 Jun; 107(6):3415-24. 1012022
    View PubMed
  144. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Reiners CA, Hentz JG, Muenter MD. Motor unit changes in sporadic idiopathic Parkinson's disease. Mov Disord. 2000 Mar; 15(2):238-43. 1012745
    View PubMed
  145. Evidente VG, Adler CH, Caviness JN, Hentz JG, Gwinn-Hardy K. Amantadine is beneficial in restless legs syndrome. Mov Disord. 2000 Mar; 15(2):324-7. 1011764
    View PubMed
  146. Gwinn-Hardy KA, Adler CH, Weaver AL, Fish NM, Newman SJ. Effect of hormone variations and other factors on symptom severity in women with dystonia. Mayo Clin Proc. 2000 Mar; 75(3):235-40. 1011750
    View PubMed
  147. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, Molho ES, Factor SA. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000 Mar-Apr; 23(2):75-81. 1011879
    View PubMed
  148. Gwinn-Hardy KA, Crook R, Lincoln S, Adler CH, Caviness JN, Hardy J, Farrer M. A kindred with Parkinson's disease not showing genetic linkage to established loci. Neurology. 2000 Jan 25; 54(2):504-7. 1011665
    View PubMed
  149. Caviness JN, Gwinn-Hardy K, Adler CH, Muenter MD. Electrophysical observations in hereditary Parkinsonism-dementia with Lewy body pathology. Mov Disord. 2000 Jan; 15(1):140-145. 1014279
    View PubMed
  150. Adler CH, Kumar R. Pharmacological and surgical options for the treatment of cervical dystonia. Neurology. 2000; 55(12 Suppl 5):S9-14. 1013616
    View PubMed
  151. Joyce JN, Adler CH. Research for new treatment of Parkinson’s disease (Review Article). Southwest Parkinson Report. 2000 Spr/Sum. 1696579
  152. Adler CH. Review of New-Onset Tic Disorders in Adults (Review Article). Journal Watch Neurology. 2000; 2:73-4. 1696581
  153. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I, Caviness JN, The Huntington Study Group. Rate of functional decline in Huntington’s disease. Neurology. 2000; 54:452-8. 1696394
    View PubMed
  154. Spitzer SM, Liss JM, Caviness JN, Adler C. The effects of familiarization on listener perception of hypokinetic and ataxic dysarthric speech. Journal of Medical Speech-Language Pathology. 2000; 8:285-93. 1696395
  155. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22; 53(7):1431-8. 1009419
    View PubMed
  156. Weiss PH, Stelmach GE, Chaiken A, Adler CH. Use of advance information for complex movements in Parkinson's disease. Parkinsonism & Related Disorders. 1999 Apr-May; 5(1-2):19-25. 1010609
  157. Evidente VG, Gwinn-Hardy K, Caviness JN, Adler CH. Risperidone is effective in severe hemichorea/hemiballismus. Mov Disord. 1999 Mar; 14(2):377-9. 1701572
    View PubMed
  158. Adler CH. Differential diagnosis of Parkinson's disease. Med Clin North Am. 1999 Mar; 83(2):349-67. 1008537
    View PubMed
  159. Evidente VG, Adler CH. How to help patients with restless legs syndrome. Discerning the indescribable and relaxing the restless. Postgrad Med. 1999 Mar; 105(3):59-61, 65-6, 73-4. 1008523
    View PubMed
  160. Farrer M, Gwinn-Hardy K, Muenter M, DeVrieze FW, Crook R, Perez-Tur J, Lincoln S, Maraganore D, Adler C, Newman S, MacElwee K, McCarthy P, Miller C, Waters C, Hardy J. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet. 1999 Jan; 8(1):81-5. 1008437
    View PubMed
  161. Evidente VG, Adler CH, Caviness JN, Gwinn-Hardy K. A pilot study on the motor effects of rimantadine in Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb; 22(1):30-2. 1008447
    View PubMed
  162. Adler CH. Botulinum toxin: Overview and use in tremor disorders (Review Article). International Tremor Foundation Newsletter. 1998 Oct. 1696573
  163. Liss JM, Spitzer S, Caviness JN, Adler C, Edwards B. Syllabic strength and lexical boundary decisions in the perception of hypokinetic dysarthric speech. J Acoust Soc Am. 1998 Oct; 104(4):2457-66. 108018
    View PubMed
  164. Evidente VG, Adler CH, Caviness JN, Gwinn KA. Effective treatment of orthostatic tremor with gabapentin. Mov Disord. 1998 Sep; 13(5):829-31. 1019013
    View PubMed
  165. Sethi KD, Obrien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchezramos J, Bertoni JM, Hauser RA. Ropinirole for the treatment of early Parkinson-disease - a 12-month experience. Arch Neurol. 1998 Sep; 55(9):1211-1216. 1020172
    View PubMed
  166. Adler CH, Singer C, Obrien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson-disease treated with levodopa-carbidopa. Arch Neurol. 1998 Aug; 55(8):1089-1095. 1020097
    View PubMed
  167. Johnstone SJ, Adler CH. Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm. Headache. 1998 May; 38(5):366-8. 1018658
    View PubMed
  168. Kurth MC, Adler CH. COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology. 1998 May; 50(5 Suppl 5):S3-14. 1021240
    View PubMed
  169. Evidente VG, Adler CH, Giannini C, Conley CR, Parisi JE, Fletcher GP. Erdheim-Chester disease with extensive intraaxial brain stem lesions presenting as a progressive cerebellar syndrome. Mov Disord. 1998 May; 13(3):576-81. 1018837
    View PubMed
  170. Caviness JN, Adler CH, Newman S, Caselli RJ, Muenter MD. Cortical myoclonus in levodopa-responsive parkinsonism. Mov Disord. 1998 May; 13(3):540-4. 1018817
    View PubMed
  171. Adler CH, Gwinn KA, Newman S. Olfactory function in restless legs syndrome. Mov Disord. 1998 May; 13(3):563-5. 1018835
    View PubMed
  172. Shannon KM, Penn RD, Kroin JS, Adler CH, Janko KA, York M, Cox SJ. Stereotactic pallidotomy for the treatment of Parkinson's disease. Efficacy and adverse effects at 6 months in 26 patients. Neurology. 1998 Feb; 50(2):434-8. 1018623
    View PubMed
  173. Evidente VG, Adler CH. Hemifacial spasm and other craniofacial movement disorders. Mayo Clin Proc. 1998 Jan; 73(1):67-71. 1018538
    View PubMed
  174. Adler CH. COMT inhibitors: novel treatments for Parkinson's disease. CNS Spectrums. 1998; 3(2):53-56. 1020311
  175. Johnstone S, Adler CH. Headache and facial pain: Response to botulinum toxin (Review Article). Benign Essential Blepharospasm Newsletter. 1998; 17(5):5. 1696572
  176. Tresilian JR, Stelmach GE, Adler CH. Stability of reach-to-grasp movement patterns in Parkinson's disease. Brain. 1997 Nov; 120(Pt 11):2093-111. 1015912
    View PubMed
  177. Uitti RJ, Wharen RE Jr, Turk MF, Lucas JA, Finton MJ, Graff-Radford NR, Boylan KB, Goerss SJ, Kall BA, Adler CH, Caviness JN, Atkinson EJ. Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients. Neurology. 1997 Oct; 49(4):1072-7. 1314295
    View PubMed
  178. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology. 1997 Aug; 49(2):393-9. 1016573
    View PubMed
  179. Teulings HL, Contreras-Vidal JL, Stelmach GE, Adler CH. Parkinsonism reduces coordination of fingers, wrist, and arm in fine motor control. Exp Neurol. 1997 Jul; 146(1):159-70. 1015563
    View PubMed
  180. O'Neill MA, Gwinn KA, Adler CH. Biofeedback for writer's cramp. Am J Occup Ther. 1997 Jul-Aug; 51(7):605-7. 1015655
    View PubMed
  181. Evidente VGH, Adler CH. Pharmacologic options for managing Parkinson's-disease. Hosp Formul. 1997 Jun; 32(6):594-610. 1017361
  182. Adler CH, Caviness JN. Dystonia secondary to electrical injury: surface electromyographic evaluation and implications for the organicity of the condition. J Neurol Sci. 1997 May 29; 148(2):187-92. 1015940
    View PubMed
  183. Adler CH. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol. 1997 Apr; 20(2):148-51. 1015935
    View PubMed
  184. Kurth MC, Adler CH, Sthilaire M, Singer C, Waters C, Lewitt P, Chernik DA, Dorflinger EE, Yoo K, Lieberman AN, Brewer M, Sainthilaire M, Pery LM, Thomas C, Turpin L, Obrien CF, Seeberger LC, Duncan KL, Caviness JN, Douglas M, Wheeler K, Riley D, Rainey P, Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations - a multicenter, double blind, randomized, placebo-controlled trial. Neurology. 1997 Jan; 48(1):81-87. 1314263
    View PubMed
  185. Lieberman A, Caviness JN, The Pramipexole Study Group. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controled, parallel-group study. Neurology. 1997; 49(162-8). 1727781
  186. Adler CH, Joyce J. Parkinson's disease and your brain (Review Article). Arizona Parkinson Report Summer, 1997. 1696570
  187. Evidente V, Adler CH. Current management of Parkinson's disease. Formulary. 1997; 32:594-610. 1696392
  188. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol. 1996 Jun; 19(3):202-12. 1025634
    View PubMed
  189. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, Hiner BC, Lieberman A, Pfeiffer RF, Rodnitzky RL, Waters CH, Muenter MD, Adler CH, Morris JL. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology. 1996 Apr; 46(4):1062-5. 1025071
    View PubMed
  190. Adler CH, Zimmerman RS, Lyons MK, Simeone F, Brin MF. Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease. Mov Disord. 1996 Jan; 11(1):79-81. 1024967
    View PubMed
  191. Adler CH, Wrabetz LG. Lesch-Nyhan variant: Dystonia, ataxia, near-normal intelligence, and no self-mutilation. Movement Disorders. 1996; 11:583-4. 1696387
    View PubMed
  192. Weiss P, Stelmach GE, Adler CH, Waterman C. Parkinsonian arm movements as altered by task difficulty. Parkinson's Disease and Related Disorders. 1996; 2:215-23. 1696388
  193. Adler CH, Stern MB, Shils J, Stecker MM. Movement analysis in generalized and hemiparkinsonism. J Human Movement Studies. 1995; 29:51-62. 1696386
  194. Adler CH. Why? I don't know! (Review Article). NSTA Newsletter 4 1995; 12(1). 1696563
  195. Pestronk A, Choksi R, Bieser K, Goldstein JM, Adler CH, Caselli RJ, George EB. Treatable gait disorder and polyneuropathy associated with high titer serum IgM binding to antigens that copurify with myelin-associated glycoprotein. Muscle & Nerve. 1994 Nov; 17(11):1293-300. 1033294
    View PubMed
  196. Adler CH, Wrabetz L, Brin MF, Hurtig HI. Cerebellar ataxia, dystonia, and tremor within a family: variable phenotypes of a single genetic disorder? Mov Disord. 1994 Mar; 9(2):155-60. 1032178
    View PubMed
  197. Stern MB, Doty RL, Dotti M, Corcoran P, Crawford D, McKeown DA, Adler CH, Gollomp S, Hurtig H. Olfactory function in Parkinson's disease subtypes. Neurology. 1994; 44:266-8. 1696385
    View PubMed
  198. Bernardi B, Zimmerman RA, Savino PJ, Adler C. Magnetic resonance tomographic angiography in the investigation of hemifacial spasm. Neuroradiology. 1993; 35(8):606-11. 1029495
    View PubMed
  199. Bennett KMB, Adler CH, Stelmach GE, Castiello U. A kinematic study of the reach to grasp movement in a patient with hemi-Parkinson disease. Neuropsychologia. 1993; 31:709-716. 1031186
    View PubMed
  200. Castiello U, Bennett KMB, Adler CH, Stelmach GE. Perturbation of the grasp component of a prehension movement in a patient with hemi-Parkinson disease. Neuropsychologia. 1993; 31:717-723. 1031197
    View PubMed
  201. Adler CH. Mechanism of action of botulinum toxin (Review Article). NSTA Newsletter 4 1993; 10(2). 1696553
  202. Adler CH, Zimmerman RA, Savino PJ, Bernardi B, Bosley TM, Sergott RC. Hemifacial spasm: evaluation by magnetic resonance imaging and magnetic resonance tomographic angiography. Ann Neurol. 1992 Oct; 32(4):502-6. 1039980
    View PubMed
  203. Dodick D, Adler CH. Tourette's syndrome. Current approaches to recognition and management. Postgrad Med. 1992 Oct; 92(5):299-302, 305-8. 1039981
    View PubMed
  204. Adler CH, Hurtig HI, Jacobson MP, Brooks ML. CPC: a woman with lung and brain masses. J Neuroimaging. 1992; 2:97-101. 1039986
  205. Arai H, Schmidt ML, Lee VMY, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ. Epitope analysis of senile plaque components in the hippocampus. Neurology. 1992; 42:1315-1322. 1040115
    View PubMed
  206. Adler CH. Dystonia, clinical overview. Clin Semin Mov Disord. 1992; 1:14-16. 1040664
  207. Adler CH. Botulinum toxin A therapy in dystonia. Hosp Pract (Off Ed). 1991 Aug 15; 26(8):35, 38, 41-2. 2135995
    View PubMed
  208. Adler CH, Galetta SL. Oculo-facial-skeletal myorhythmia in Whipple disease: treatment with ceftriaxone. Ann Intern Med. 1990 Mar 15; 112(6):467-9. 1035121
    View PubMed
  209. Adler CH, Stern MB, Brooks ML. Parkinsonism secondary to bilateral striatal fungal abscesses. Mov Disord. 1989; 4(4):333-7. 1046955
    View PubMed
  210. Adler CH, Meller E, Goldstein M. Receptor reserve at functional alpha-2 adrenergic autoreceptors in the rat cerebral cortex. J Pharmacol Exp Ther. 1987; 240:508-515. 1041017
    View PubMed
  211. Meller E, Helmer-Matyjek E, Bohmaker K, Adler CH, Friedhoff AJ, Goldstein M. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur J Pharmacol. 1986 Apr 16; 123(2):311-4. 1052857
    View PubMed
  212. Goldstein M, Kusano N, Adler C, Meller E. Characterization of central neuropeptide Y receptor binding sites and possible interactions with alpha 2-adrenoceptors. Prog Brain Res. 1986; 68:331-5. 1052858
    View PubMed
  213. Adler CH, Meller E, Goldstein M. Recovery of alpha 2-adrenoceptor binding and function after irreversible inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Eur J Pharmacol. 1985 Oct 8; 116(1-2):175-8. 1050069
    View PubMed
  214. Adler CH, Robin M, Adler MW. Tolerance to morphine-induced mydriasis in the rat pupil. Life Sci. 1981 Jun 1; 28(22):2469-75. 1112654
    View PubMed
  215. Adler C, Keren O, Korczyn AD. Tolerance to the Mydriatic effects of morphine in mice. J Neural Transm. 1980; 48(1):43-7. 1110420
    View PubMed
  216. Klemfuss H, Tallarida RJ, Adler CH, Adler MW. Morphine-induced mydriasis and fluctuation in the rat: time and dose relationships. Journal of Pharmacology & Experimental Therapeutics. 1979 Jan; 208(1):91-5. 1108313
    View PubMed
  217. Adler MW, Adler CH. Toxicity to heavy metals and relationship to seizure thresholds. Clin Pharmacol Ther. 1977 Nov; 22(5 Pt 2):774-9. 1108312
    View PubMed